[1] SHIM R,WEN S W,WANROOY B J,et al. Stroke severity,and not cerebral infarct location,increases the risk of infection[J].Transl Stroke Res,2020,11(3):387-401. [2] LEHMAN S M,MEAMS G,RANKIN D,et al. Design and preclinical development of a phage product for the treatment of antibiotic-resistant staphylococcus aureus infections[J].Viruses,2019,11(1):43-45. [3] CASTRO B E,BERRIO M,VARGAS M L,et al. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America[J].J Antimicrob Chemother,2020,75(9):2424-2431. [4] FEMANDEZ-BARAT L,MMOTOS A,PANIGADA M,et al. Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients[J].Crit Care,2019,23(1):251-253. [5] 崔丽英. 脑卒中防治[M]. 北京:科学出版社,2011:215-227. [6] 吴小军,聂汉祥. 呼吸系统疾病并发症鉴别预测与治疗[M]. 上海:科学技术文献出版社,2011:158-165. [7] 《抗菌药物临床应用指导原则》修订工作组. 抗菌药物临床应用指导原则:2015年版[M]. 北京:人民卫生出版社,2015:31-33. [8] 王力红,朱士俊. 医院感染学[M]. 北京:人民卫生出版社,2014:22-23. [9] MOORE J A,MEAKIN M,EARL M H,et al. Effects of caspofungin,tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin[J].J Glob Antimicrob Resist,2020,22(15):283-289. [10] BHATIA A,MASTIM M,SHAH M,et al. Efficacy and safety of a novel broad-spectrum Anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections:a phase 3,openlabel,randomized study[J].J Assoc Physicians India,2020,68(8):30-36. [11] 马玲,郑鹏程,郑瑞,等. 万古霉素与利奈唑胺在中国治疗耐甲氧西林金黄色葡萄球菌感染的医院获得性肺炎的成本-效果分析[J].中国医院药学杂志,2019,39(22):2314-2318. [12] 桂文林,李建兰,刘权盼.基于奇异谱的中国季度 GDP分解和产出缺口估计[J].统计与信息论坛,2018,33(7):63-74.
2022, Vol. 39 
